Compare First Solar, Inc. (FSLR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Novo Nordisk A/S — how do they compare? First Solar, Inc. trades at $178.48 (market cap $19.22B), while Novo Nordisk A/S trades at $38.44 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 8.6× First Solar, Inc.'s market cap, and Novo Nordisk A/S pays a 4.71% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Novo Nordisk A/S for 116 Days on average.
| FSLR | NVO | |
|---|---|---|
Market Cap | $19.22B | $165.31B |
Volume | 2,067,793 | 11,432,838 |
Sector | Energy | Health |
52-Week High | $318.30 | $63.98 |
52-Week Low | $172.11 | $35.29 |
Typical Hold Time | 76 Days | 116 Days |
Enterprise Value | $17.69B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $178.36, down 0.98% with bearish technical signals despite strong fundamentals. The stock shows robust revenue growth from $2.6B in 2022 to $5.2B in 2025, with net income margins expanding to 32.47%. Recent patent litigation against JA Solar and increased put option activity reflect mixed sentiment. Technical indicators show resistance at $182 and support at $175, with moving averages signaling bearish momentum.
FSLR presents a value opportunity with attractive valuation ratios (P/E 11.03, P/S 3.58) and analyst consensus price target of $267.59 (50% upside). Risks include sector-wide pressure from high borrowing costs and political uncertainty. Strong cash flow generation ($2.06B operating cash flow) and consistent earnings beats support long-term growth prospects despite near-term technical weakness.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
